Physician profile

Robert E Parke

Pulmonary Disease · Orange, CA

NPI 1962470161

$7,877.85

in general payments reported to CMS, 2019-2025

34 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,589.82 2019-2022
Astrazeneca Pharmaceuticals Lp $1,165.41 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $743.24 2019-2021
Glaxosmithkline, LLC. $732.21 2019-2022
Janssen Pharmaceuticals, INC $542.40 2019-2022
Insmed, INC. $457.45 2019-2020
Sanofi-Aventis U.S. LLC $360.82 2019-2020
Sanofi Pasteur INC. $274.15 2019-2020
Amarin Pharma, INC. $273.78 2019-2021
Genentech USA, INC. $263.74 2019
Novo Nordisk INC $204.85 2019-2020
Mylan Specialty L.P. $199.85 2019-2022
Philips North America LLC $168.50 2019-2020
Intersect Ent, INC. $115.31 2019
Allergan, INC. $94.03 2019-2020
Show all 34 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert E Parke

$7,877.85

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/179331/robert-e-parke

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.